foxo4 dri peptide senolytic 2023 2024 study Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment FOXO4-DRI part 1 #peptide #molecule

short rodent studies have not reported overt tumors, but long-term and human data are absent [5]

Thymosin Beta-4 (TB-500) is a 43-amino acid peptide involved in actin cytoskeleton organization, cell migration, and angiogenesis, while Body Protection Compound-157 (BPC-157) is a 15-amino acid gastric peptide with cytoprotective, angiogenic, and anti-inflammatory properties

The results showed no alteration in blood and clinical test parameters compared to the control group

A important study by Kozlovskaya et al

Start here

Given its prominent proangiogenic effects, deciphering the mechanistic basis of its vascular regenerative actions is critically important